Orion Oyj (ORINY) Stock

About Orion Oyj

Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug formulation. Its operations extend across Finland, the Nordic region, wider Europe, North America, and various international markets. The company's diverse product portfolio encompasses both prescribed medications and over-the-counter (OTC) healthcare solutions. This includes notable offerings such as Nubeqa for prostate cancer therapy; Dexdor and Precedex, utilized as sedatives in intensive care settings; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute heart failure decompensation; and Fareston for breast cancer management. Additionally, a range of Easyhaler devices—like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol—are provided for managing asthma and chronic obstructive pulmonary disease (COPD). Beyond human medicine, the firm supplies a suite of veterinary medications, including products such as Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. It also produces APIs for both proprietary and generic pharmaceutical products and offers specialized contract manufacturing capabilities. Furthermore, Orion Oyj distributes veterinary medicines manufactured by other global pharmaceutical entities. Its clientele spans a broad spectrum of healthcare stakeholders, from specialist and general physicians, veterinarians, and pharmacists to hospitals, healthcare centers, clinics, laboratories, and directly to consumers who own pets. Strategic alliances include a collaboration with Propeller Health aimed at integrating its Easyhaler® product range for asthma and COPD management with digital health solutions. Additionally, it holds a research collaboration and licensing deal with Alligator Bioscience AB (publ) focused on pioneering novel bispecific antibody-based cancer treatments. Established in 1917, Orion Oyj maintains its corporate headquarters in Espoo, Finland.

Orion Oyj is headquartered in FI.

Orion Oyj (ORINY) stock trades at $38.54 with a market capitalization of $21.69B. The stock is valued at a price-to-earnings (P/E) ratio of 18.22, price-to-book of 8.59, price-to-sales of 4.94. Over the past 52 weeks the stock has ranged between $30.89 and $42.75, and currently trades 9.8% below its 52-week high. It pays a dividend yielding 2.70%.

On profitability, Orion Oyj generates a return on equity (ROE) of 48.73%, above the typical market range of roughly 12-15%, return on capital employed of 52.00%, an operating margin of 34.11%, a net profit margin of 27.12%.

In its most recent fiscal year, Orion Oyj reported annual revenue of $1.9B, net profit of $481.0M. Over the last 5 fiscal years, revenue grew at an average annual rate of 11.9%, and net profit grew at an average annual rate of 16.9%. Over that span net profit grew faster than revenue, so net margin widened.

The balance sheet shows a debt-to-equity ratio of 0.29 (debt below half of shareholders' equity), a current ratio of 1.77, total assets of $2.0B, $161.0M in cash and equivalents.

ORINY has an average daily trading volume of 158 shares, a beta of 0.29 (historically less volatile than the overall market).

Official website: www.orionpharma.com

Orion Oyj by the numbers, 2016–2025

Between 2016 and 2025 Orion Oyj reported revenue of $1.1B rising to $1.9B, a change of +76.0% across 10 years. Compounded, revenue has grown 11.9% a year over five years, 12.1% over three, 22.6% over the last twelve months. Net profit rose to $481.0M.

Operating margin went from 29.3% in 2016 to 33.4% in 2025, a gain of 4.1 percentage points. The most recent net margin is 27.12%. On a trailing twelve-month basis to Mar '26, revenue is $2.0B and net profit $530.0M.

Borrowings rose from $153.0M to $305.0M, cash on hand is $199.3M, cash from operations was $317.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 31.8% over five years, and was 37.4% in the most recent year.

The share price itself has compounded at 16.2% a year over five years, 25.4% over three, 1.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Orion Oyj (ORINY) — frequently asked questions